A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumoursMichael Warso, Tapas K. Das Gupta, Jon Richards et al.|British Journal of Cancer|2013Cited by 182
Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer CellsBrad N. Taylor, Tapas K. Das Gupta, Fatima Lekmine et al.|Cancer Research|2009Cited by 181
Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium StudyRishi Lulla, Maryam Fouladi, Stewart Goldman et al.|Neuro-Oncology|2016Cited by 140
A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and AktRajeshwari R. Mehta, Tapas K. Das Gupta, Tohru Yamada et al.|Angiogenesis|2011Cited by 115
A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cellsTohru Yamada, Tapas K. Das Gupta, Rajeshwari R. Mehta et al.|Molecular Cancer Therapeutics|2009Cited by 114